Key points are not available for this paper at this time.
Targetable IC components are upregulated in the majority of endocrine therapy-resistant LumB cases. Our findings provide rationale for IC inhibition in poor-outcome ER-positive breast cancer.
Anurag et al. (Mon,) studied this question.